News | December 20, 2006

FDA Clears New Thrombectomy System

The latest in thrombus removal devices from Possis has received FDA clearance — the new AngioJet Ultra Thrombectomy System is the next-generation, re-engineered version of the company’s AngioJet Rheolytic Thrombectomy System.

AngioJet is marketed for blood clot removal (thrombectomy) from arterial and venous blood vessels. Possis says the new Ultra System features a simple and fast setup process, the flexibility to use a broad range of catheters, a sleeker design, lighter weight, and handling improvements that make it significantly easier to maneuver than the previous AngioJet drive unit.

Possis will conduct market evaluations of the Ultra System at key sites throughout the U.S. A full-market release is anticipated by Summer 2007.

AngioJet Systems are installed in 95 percent of top coronary labs in the U.S., according to a company release, with more than 1,700 systems are installed across the country. Possis currently estimates its total realizable market opportunity for AngioJet thrombectomy in the U.S. at $440 million, increasing to $675 million by 2010.

Related Content

JETi Thrombectomy System Safe and Effective for Deep Vein Thrombosis
News | Thrombectomy Devices | February 12, 2019
A study presented at the 2018 annual meeting of the Cardiovascular and Interventional Radiology Society of Europe (...
Delayed Clot Removal Still Improves Quality of Life Post-Stroke
News | Thrombectomy Devices | February 05, 2019
Stroke survivors have better quality of life three months after their stroke if the clot that caused the stroke was...
An assortment of Boston Scientific AngioJet rheolytic thrombectomy catheters. These devices use high-velocity saline jets to entrain thrombus, resulting in microfragmentation and removal. Thrombectomy is also referred to as embolectomy.

An assortment of Boston Scientific AngioJet rheolytic thrombectomy catheters. These devices use high-velocity saline jets to entrain thrombus, resulting in microfragmentation and removal.

Feature | Thrombectomy Devices | January 22, 2019 | Dave Fornell, Editor
Catheter-based blood clot removal a decade ago was a standard of care for acute coronary revascularization, but decli
Cerenovus Launches Global Registry for EmboTrap II Revascularization Device
News | Thrombectomy Devices | January 16, 2019
Cerenovus, of Johnson & Johnson Medical Devices Companies, recently launched the EXCELLENT Registry to collect and...
First Commercial Ekos Control Unit 4.0 Products Shipped to Europe
News | Thrombectomy Devices | November 21, 2018
November 21, 2018 — BTG plc announced the first Ekos CU 4.0 units have been shipped from BTG’s facility in Bothell, W
Medtronic MindFrame Capture LP Revascularization Device Recalled.
News | Thrombectomy Devices | May 21, 2018
Medtronic and the U.S. Food and Drug Administration (FDA) announced a Class I Urgent Medical Device Recall of the...
Stryker Trevo Retriever Thrombectomy Device Approved for Stroke Treatment Up to 24 Hours
Technology | Thrombectomy Devices | February 15, 2018
The U.S. Food and Drug Administration (FDA) has expanded the indication for Stryker's Trevo Retriever as a front-line...
Brain-scan guided emergency stroke treatment can save more lives
News | Thrombectomy Devices | January 25, 2018
January 25, 2018 – Advances in brain imaging can identify a greater number of stroke patients who can receive therapy
global thrombectomy devices market, Allied Market Research report, 2022
News | Thrombectomy Devices | January 05, 2017
January 5, 2017 — A new report published by Allied Market Research forecasts that the global...
Neuravi, EmboTrap II stent retriever, thrombectomy device, acute stroke, European launch, CE Mark
News | Thrombectomy Devices | September 28, 2016
Neuravi recently announced Conformité Européenne (CE) Mark approval and launch of the company’s newly available...
Overlay Init